Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hicran Doğru & İbrahim Selçuk Esin. (2022) Counsellors’ position in the child–teacher-parent axis in attention-deficit/hyperactivity disorder and learning disorders. British Journal of Guidance & Counselling 50:5, pages 732-742.
Read now
Read now
M Janelle Cambron-Mellott, Jaromir Mikl, Joana E Matos, Jennifer G Erensen, Kathleen Beusterien, Marc J Cataldo, Bernadette Hallissey & Gregory W Mattingly. (2021) Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment. Patient Preference and Adherence 15, pages 1061-1073.
Read now
Read now
Ann Childress, Bernice Ponce De Leon & Mark Owens. (2018) QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above. Expert Opinion on Drug Delivery 15:12, pages 1263-1270.
Read now
Read now
Articles from other publishers (30)
Kaitlyn McKenna, Sithara Wanni Arachchige Dona, Lisa Gold, Angela Dew & Ha N. D. Le. (2023) Barriers and Enablers of Service Access and Utilization for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Systematic Review. Journal of Attention Disorders 28:3, pages 259-278.
Crossref
Crossref
A. B. Palchik. (2023) Encephalopathy of Prematurity: Invisible Cause of Cognitive and Behavioral Disorders. Human Physiology 49:3, pages 316-322.
Crossref
Crossref
Andrew J. Cutler, Katsumi SuzukiBrittney StarlingKanan BalakrishnanMarina KomaroffSuzanne MeevesMariacristina CastelliAnn Childress. (2023)
d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and
Post Hoc
Effect Size Analyses from a Pivotal Trial
. Journal of Child and Adolescent Psychopharmacology 33:5, pages 176-182.
Crossref
Crossref
А. B. Palchik. (2023) Encephalopathy of Prematurity: Invisible Cause of the Cognitive and Behavioural Disorders. Физиология человека 49:3, pages 126-133.
Crossref
Crossref
Nazar Muhammad, Bhavani G Murugesan, Prakamya Singal, Angelica Antai & Lakshit Jain. (2023) Diagnostic Dilemma of Differentiating Attention-Deficit/Hyperactivity Disorder (ADHD) From Mood Disorders and Other Common Psychiatric Illnesses in Substance Use Patient Population. Cureus.
Crossref
Crossref
Soroush Bakhshi, Mehdi Tehrani-Doost & Seyed Amir Hossein Batouli. (2023) Fronto-Cerebellar Neurometabolite Alterations After Methylphenidate in Children and Adolescents With ADHD: A Proton Magnetic Resonance Spectroscopy Study. Journal of Attention Disorders 27:4, pages 410-422.
Crossref
Crossref
Mehmet Akif Akıncı, Necati Uzun & Cem Gökçen. (2022) The Effects of Exercise in the Treatment of Attention Deficit Hyperactivity Disorder. Turkish Journal of Child and Adolescent Mental Health 29:3, pages 130-136.
Crossref
Crossref
Amy Pipe, Nisha Ravindran, Angela Paric, Beth Patterson, Michael Van Ameringen & Arun V. Ravindran. (2022) Treatments for child and adolescent attention deficit hyperactivity disorder in low and middle-income countries: A narrative review. Asian Journal of Psychiatry 76, pages 103232.
Crossref
Crossref
Michael A. FederDouglas M. BrodmanZi Chun YangVanessa Y. T. NgSamantha GlickmanJacqueline SmithArgelinda BaroniErica WillheimTimothy L. Verduin. (2022) I'm Coming Home: Providing Parent Training to Support Inpatient Discharge Programs. The ADHD Report 30:5, pages 1-7.
Crossref
Crossref
Cynthia P. Paidipati, Janet A. Deatrick, Ricardo B. Eiraldi, Connie M. Ulrich, Jamil M. Lane & Bridgette M. Brawner. (2021) Caregivers' perspectives on the contextual influences within family management for ethnically diverse children with ADHD. Journal for Specialists in Pediatric Nursing 27:2.
Crossref
Crossref
Andrew J. Cutler, Katsumi SuzukiBrittney StarlingKanan BalakrishnanMarina KomaroffMariacristina CastelliSuzanne MeevesAnn C. Childress. (2022) Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study. Journal of Child and Adolescent Psychopharmacology 32:2, pages 89-97.
Crossref
Crossref
Tanu Gupta & Kartik Singhai. 2022. Handbook of Research on Clinical Applications of Meditation and Mindfulness-Based Interventions in Mental Health. Handbook of Research on Clinical Applications of Meditation and Mindfulness-Based Interventions in Mental Health
144
152
.
Elena Eggert, Annet Bluschke, Adam Takacs, Maximilian Kleimaker, Alexander Münchau, Veit Roessner, Moritz Mückschel & Christian Beste. (2021) Perception-Action Integration Is Modulated by the Catecholaminergic System Depending on Learning Experience. International Journal of Neuropsychopharmacology 24:7, pages 592-600.
Crossref
Crossref
Annet Bluschke, Nicolas Zink, Moritz Mückschel, Veit Roessner & Christian Beste. (2020) A novel approach to intra-individual performance variability in ADHD. European Child & Adolescent Psychiatry 30:5, pages 733-745.
Crossref
Crossref
Gregory W. Mattingly & Joel Young. (2021) A clinician’s guide for navigating the world of attention deficit hyperactivity disorder medications. CNS Spectrums 26:2, pages 104-114.
Crossref
Crossref
Mingming Zhou, Jodi Gresack, Jia Cheng, Kunihiro Uryu, Lars Brichta, Paul Greengard & Marc Flajolet. (2018) CK1δ over-expressing mice display ADHD-like behaviors, frontostriatal neuronal abnormalities and altered expressions of ADHD-candidate genes. Molecular Psychiatry 25:12, pages 3322-3336.
Crossref
Crossref
Martin A. Katzman, Greg Mattingly, Larry J. Klassen, Marc J. Cataldo & Graeme A. E. Donnelly. (2020) Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults. Journal of Clinical Psychopharmacology 40:6, pages 579-587.
Crossref
Crossref
Bobbi Fleiss, Pierre Gressens & Helen B. Stolp. (2020) Cortical Gray Matter Injury in Encephalopathy of Prematurity: Link to Neurodevelopmental Disorders. Frontiers in Neurology 11.
Crossref
Crossref
Vincent E. Horne, Kevin Bielamowicz, Jessica Nguyen, Susan Hilsenbeck, Holly Lindsay, Rona Sonabend, Alexis C. Wood, Fatih Okcu & Stephanie Sisley. (2020) Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatric Blood & Cancer 67:7.
Crossref
Crossref
Moritz Mückschel, Veit Roessner & Christian Beste. (2020) Task experience eliminates catecholaminergic effects on inhibitory control – A randomized, double-blind cross-over neurophysiological study. European Neuropsychopharmacology 35, pages 89-99.
Crossref
Crossref
Gideon Koren, Yael Barer & Asher Ornoy. (2020) Fetal safety of methylphenidate—A scoping review and meta analysis. Reproductive Toxicology 93, pages 230-234.
Crossref
Crossref
Maik Pertermann, Annet Bluschke, Veit Roessner & Christian Beste. (2019) The Modulation of Neural Noise Underlies the Effectiveness of Methylphenidate Treatment in Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 4:8, pages 743-750.
Crossref
Crossref
Wiebke Bensmann, Nicolas Zink, Veit Roessner, Ann-Kathrin Stock & Christian Beste. (2019) Catecholaminergic effects on inhibitory control depend on the interplay of prior task experience and working memory demands. Journal of Psychopharmacology 33:6, pages 678-687.
Crossref
Crossref
Sara SoufsafPhilippe RobaeyGuillaume BonnefoisFahima NekkaJun Li. (2019) A Quantitative Comparison Approach for Methylphenidate Drug Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. Journal of Child and Adolescent Psychopharmacology 29:3, pages 220-234.
Crossref
Crossref
Rachel L. Navarra & Barry D. Waterhouse. (2019) Considering noradrenergically mediated facilitation of sensory signal processing as a component of psychostimulant-induced performance enhancement. Brain Research 1709, pages 67-80.
Crossref
Crossref
Gonzalo Salazar de Pablo, Julio David Vaquerizo Serrano, Sandra Gómez Vallejo, Javier Sánchez Cerezo & Carmen Moreno Ruiz. 2019. Frontiers in Psychiatry. Frontiers in Psychiatry
429
451
.
Nathan S. Teuscher, Carolyn R. SikesRuss McMahenDorothy Engelking. (2018) Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology 38:5, pages 467-474.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2018) Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use. Drugs & Therapy Perspectives 34:9, pages 411-419.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2017) Methylphenidate extended-release orally disintegrating tablets (Cotempla XR-ODT™) in attention-deficit hyperactivity disorder in children aged 6–17 years: a profile of their use. Drugs & Therapy Perspectives 34:2, pages 43-49.
Crossref
Crossref
Annet Bluschke, Julia Friedrich, Marie Luise Schreiter, Veit Roessner & Christian Beste. (2018) A comparative study on the neurophysiological mechanisms underlying effects of methylphenidate and neurofeedback on inhibitory control in attention deficit hyperactivity disorder. NeuroImage: Clinical 20, pages 1191-1203.
Crossref
Crossref